Compare Gap Inc (GAP) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Gap Inc trades at $23.16 (market cap $8.21B), while Vertex Pharmaceuticals Incorporated trades at $510.84 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 15.5× Gap Inc's market cap, and Gap Inc pays a 3% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| GAP | VRTX | |
|---|---|---|
Market Cap | $8.21B | $127.55B |
Volume | 5,192,917 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $557.96 |
52-Week Low | $18.35 | $407.37 |
Typical Hold Time | 37 Days | 120 Days |
Enterprise Value | $11.44B | $121.68B |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap trades at $23.61, down 0.76% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $25.67. The stock shows strong fundamentals with a low P/E of 7.04, robust ROE of 33.78%, and net income margin expansion to 8.14% in 2025. Recent earnings beats in Q1 and Q2 2026 and strategic moves into music partnerships signal brand revitalization efforts.
The outlook is positive given undervaluation, earnings momentum, and strategic initiatives, but risks include reliance on Old Navy's turnaround and competitive pressures. Upside to the price target offers potential, supported by institutional buying interest and solid cash flow generation.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
